Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 254 clinical trials
Molecular Analysis for Therapy Choice (MATCH)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

solid tumour
gonadotropin
brain tumor
nivolumab
corticosteroids
  • 6595 views
  • 20 Oct, 2022
  • 906 locations
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether …

lung cancer
solid tumour
erbb2
carcinoma
pancreatic adenocarcinoma
  • 179 views
  • 28 Oct, 2022
  • 13 locations
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

solid tumour
erbb2
stage iv non-small cell lung cancer
lymphoma
salvage therapy
  • 110 views
  • 27 Oct, 2022
  • 34 locations
Hexvix Cystoscopy for Detection of Bladder Cancer

Hexvix is a photo-dynamic agent which fluoresces and is taken by tumor tissue in the bladder. When viewed under blue light cystoscopy, tumor areas appear red.

cystoscopy
hexvix
  • 23 views
  • 07 Nov, 2020
  • 1 location
Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

RATIONALE: Tamoxifen may slow the growth of tumor cells and may be an effective treatment for patients with metastatic bladder cancer that did not respond to previous chemotherapy. PURPOSE: This phase II trial is studying how well tamoxifen works in treating patients with metastatic bladder cancer that did not respond …

tumor cells
  • 35 views
  • 07 Nov, 2020
  • 1 location
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

growth factors
absolute neutrophil count
platelet count
monoclonal antibodies
growth factor
  • 0 views
  • 18 Oct, 2022
  • 42 locations
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors

neuropathy
solid tumour
cancer chemotherapy
biologic agents
serum pregnancy test
  • 43 views
  • 30 Apr, 2022
  • 7 locations
A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma

A study of the efficacy and safety of probiotics in immunotherapy of urothelial carcinoma.

  • 0 views
  • 23 Mar, 2022
  • 1 location
SArcopenia, Mobility, PHYsical Activity and Post-operative Risk of Bladder Carcinoma in the Elderly (SAMPHYR)

Sarcopenia is associated with lower prognosis in solid tumors, but this has not been studied in bladder carcinoma requiring cystectomy. According to EWGSOP recommendations, the diagnosis

mass measurement
radical cystectomy
grip
bladder carcinoma
carcinoma
  • 20 views
  • 30 Jan, 2022
  • 2 locations
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for …

  • 1 views
  • 06 Nov, 2021
  • 1 location